Matt Dallas is the Chief Financial Officer of Pulmocide. He brings more than 20 years of financial management experience in the life sciences industry. Most recently, he served as Chief Financial Officer of Zealand Pharma, a Danish biotechnology research company that designs and develops peptide-based medicines mainly focusing on metabolic diseases, like diabetes and obesity. Prior to Zealand, Matt held CFO roles with AVEO Oncology and CoLucid Pharmaceuticals. At CoLucid, he helped lead the company’s initial public offering and subsequent acquisition by Eli Lilly and Company. In addition, Matt previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation.
Matt holds a B.S. in finance from the University of Tennessee, Knoxville and serves on the University’s Finance Department Advisory Council.